A new treatment for hepatitis C, Zepatier, has received approval from the US Food and Drug Administration (FDA), Merck & Co. announced in a statement. After this, the company’s new drug will be the latest to hit the drug market dominated by Gilead Sciences.

Once-daily drug Zepatier is a combination of grazoprevir and elbasvir. The FDA has approved the drug in the US as a treatment of the most common type of hepatitis C, Merck added. Americans with genotype 1 and genotype 4 will take the pill as a treatment.

Once the treatment hits the drug market, its competition will be with other expensive hepatitis C drugs of Gilead and AbbVie Inc. Sovaldi and Harvoni of Gilead earned more than $14 billion in first nine months of the last year. The reason behind that was Sovaldi’s price of 84,000 for a typical course and Harvoni’s $94,500 price.

Gilead’s first challenger was AbbVie which launched its Viekira Pak in 2014. But the treatment could not affect much of Gilead. In the same time of 2015 when Gilead’s drug made over $14 billion, Viekira earned just $1.1 billion. Viekira costs approximately $83,000 a patient for a standard course.

As Merck’s Zepatier has a list price of about $54,600 for a 12-week regimen, the company believes it may give a jolt to its competitors. “The price has been chosen after considering that the majority of patients with chronic hepatitis C haven’t been treated, in some cases due to cost constraints. Plans are to seek broad coverage of the drug across commercial and public insurers”, Merck said.

Analysts also think Zepatier has the ability to make a special place in drug market. Bernstein analyst Tim Anderson said Merck may have 11% share of the hepatitis C market next year.